FINESSE; Optimization of albuminuria lowering therapies to individual patients with CKD using FINErenone and SEmaglutide (FINESSE-CKD)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506434-69-00

Acronym

17456

Enrollment

Registered

2024-04-30

Start date

2025-02-11

Completion date

Unknown

Last updated

2024-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease

Brief summary

Endpoint parameter is the percentage change from baseline in UACR.

Detailed description

Percentage change from baseline in UACR., Number of missed urine collection in the remote (@home) setting

Interventions

DRUGRybelsus 7 mg tablets

DRUGKerendia 20 mg film-coated tablets

DRUGRybelsus 3 mg tablets

DRUGRybelsus 14 mg tablets

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Endpoint parameter is the percentage change from baseline in UACR.	—

Secondary

Measure	Time frame
Percentage change from baseline in UACR., Number of missed urine collection in the remote (@home) setting	—

Countries

Denmark, Italy, Netherlands, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026